ArriVent BioPharma (AVBP) Competitors $20.07 +0.23 (+1.17%) As of 10:23 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock AVBP vs. TLX, SRRK, CRNX, RARE, XENE, VKTX, AMRX, KYMR, MOR, and BHCShould you be buying ArriVent BioPharma stock or one of its competitors? The main competitors of ArriVent BioPharma include Telix Pharmaceuticals (TLX), Scholar Rock (SRRK), Crinetics Pharmaceuticals (CRNX), Ultragenyx Pharmaceutical (RARE), Xenon Pharmaceuticals (XENE), Viking Therapeutics (VKTX), Amneal Pharmaceuticals (AMRX), Kymera Therapeutics (KYMR), MorphoSys (MOR), and Bausch Health Cos (BHC). These companies are all part of the "pharmaceutical products" industry. ArriVent BioPharma vs. Its Competitors Telix Pharmaceuticals Scholar Rock Crinetics Pharmaceuticals Ultragenyx Pharmaceutical Xenon Pharmaceuticals Viking Therapeutics Amneal Pharmaceuticals Kymera Therapeutics MorphoSys Bausch Health Cos Telix Pharmaceuticals (NASDAQ:TLX) and ArriVent BioPharma (NASDAQ:AVBP) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, risk, earnings, media sentiment, profitability, dividends, valuation and institutional ownership. Does the media favor TLX or AVBP? In the previous week, Telix Pharmaceuticals had 21 more articles in the media than ArriVent BioPharma. MarketBeat recorded 33 mentions for Telix Pharmaceuticals and 12 mentions for ArriVent BioPharma. ArriVent BioPharma's average media sentiment score of 1.34 beat Telix Pharmaceuticals' score of -0.20 indicating that ArriVent BioPharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Telix Pharmaceuticals 2 Very Positive mention(s) 4 Positive mention(s) 9 Neutral mention(s) 4 Negative mention(s) 1 Very Negative mention(s) Neutral ArriVent BioPharma 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is TLX or AVBP more profitable? Telix Pharmaceuticals' return on equity of 0.00% beat ArriVent BioPharma's return on equity.Company Net Margins Return on Equity Return on Assets Telix PharmaceuticalsN/A N/A N/A ArriVent BioPharma N/A -55.40%-51.97% Which has higher valuation and earnings, TLX or AVBP? Telix Pharmaceuticals has higher revenue and earnings than ArriVent BioPharma. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTelix Pharmaceuticals$516.72M6.13$32.93MN/AN/AArriVent BioPharmaN/AN/A-$80.49M-$4.02-4.90 Do insiders & institutionals have more ownership in TLX or AVBP? 9.5% of ArriVent BioPharma shares are owned by institutional investors. 18.6% of ArriVent BioPharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Do analysts rate TLX or AVBP? Telix Pharmaceuticals presently has a consensus target price of $22.33, indicating a potential upside of 138.73%. ArriVent BioPharma has a consensus target price of $39.14, indicating a potential upside of 98.74%. Given Telix Pharmaceuticals' higher probable upside, equities analysts clearly believe Telix Pharmaceuticals is more favorable than ArriVent BioPharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Telix Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80ArriVent BioPharma 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.00 SummaryTelix Pharmaceuticals and ArriVent BioPharma tied by winning 6 of the 12 factors compared between the two stocks. Get ArriVent BioPharma News Delivered to You Automatically Sign up to receive the latest news and ratings for AVBP and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AVBP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AVBP vs. The Competition Export to ExcelMetricArriVent BioPharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$775.68M$3.10B$5.77B$9.76BDividend YieldN/A2.28%6.66%4.49%P/E Ratio-4.9020.8683.0526.39Price / SalesN/A391.41527.23108.99Price / CashN/A43.5325.7028.92Price / Book3.208.1011.006.58Net Income-$80.49M-$53.35M$3.28B$265.84M7 Day Performance2.53%-0.29%-0.19%-0.26%1 Month Performance5.55%9.18%8.33%5.82%1 Year Performance-24.25%10.11%53.31%22.47% ArriVent BioPharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AVBPArriVent BioPharma2.4899 of 5 stars$20.07+1.2%$39.14+95.0%-25.8%$821.95MN/A-5.0440Positive NewsTLXTelix PharmaceuticalsN/A$9.38-1.8%$22.33+138.1%N/A$3.17B$637.77M0.00N/AAnalyst RevisionHigh Trading VolumeSRRKScholar Rock4.512 of 5 stars$32.66+0.0%$45.75+40.1%+256.1%$3.14B$33.19M-11.22140News CoveragePositive NewsCRNXCrinetics Pharmaceuticals3.7895 of 5 stars$32.95+6.3%$68.86+109.0%-37.2%$3.11B$1.04M-8.02210News CoveragePositive NewsRAREUltragenyx Pharmaceutical4.5173 of 5 stars$32.01+6.9%$81.50+154.6%-43.6%$3.09B$560.23M-5.791,294Positive NewsXENEXenon Pharmaceuticals2.6793 of 5 stars$39.14+1.1%$53.20+35.9%-2.6%$3.02B$9.43M-11.03210News CoveragePositive NewsAnalyst ForecastVKTXViking Therapeutics4.1153 of 5 stars$26.83-0.8%$86.92+223.9%-57.1%$3.02BN/A-17.5420Positive NewsAnalyst RevisionAMRXAmneal Pharmaceuticals3.0534 of 5 stars$9.47-1.0%$11.60+22.6%+10.6%$2.98B$2.79B948.458,100Positive NewsKYMRKymera Therapeutics3.5118 of 5 stars$40.00-2.9%$58.76+46.9%-15.9%$2.87B$47.07M-11.55170Positive NewsMORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28M-5.45730BHCBausch Health Cos4.4455 of 5 stars$7.68+3.4%$9.00+17.3%+29.6%$2.84B$9.63B29.5620,700Positive News Related Companies and Tools Related Companies Telix Pharmaceuticals Competitors Scholar Rock Competitors Crinetics Pharmaceuticals Competitors Ultragenyx Pharmaceutical Competitors Xenon Pharmaceuticals Competitors Viking Therapeutics Competitors Amneal Pharmaceuticals Competitors Kymera Therapeutics Competitors MorphoSys Competitors Bausch Health Cos Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AVBP) was last updated on 9/3/2025 by MarketBeat.com Staff From Our PartnersHow “Trump’s New Dollar” Could Impact Your WealthPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe $365M annual revenue crypto play While Bitcoin generates zero operational revenue, one DeFi protocol qu...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ArriVent BioPharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ArriVent BioPharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AVBP Stock Alerts